SCAN HERE

Visit the Biosimilar Hub to watch interviews with peers, sharing their experiences with biosimilar medicines

biosimilarhub.com.au

BIOSIMILAR MEDICINES ESSENTIALS

A biosimilar medicine is a **highly similar version** of an already registered biological medicine – the 'reference' biological medicine.[1]

Biosimilar medicines are **approved on the totality of evidence** gathered through a stepwise approach of comprehensive preclinical assessments and a tailored clinical program.[1–4]

Australian regulations require a biosimilar medicine to have no clinically meaningful differences and to be **therapeutically equivalent to its reference product**.[2]

With biosimilar medicines approved in Europe since 2006 and in Australia since 2010, their use is supported by **over a decade of real-world clinical experience**.[5,6]

Biosimilar medicines must **comply with post-registration pharmacovigilance requirements**. This can include a Risk Management Plan (RMP) and Periodic Safety Update Reports (PSURs).[7]

If brand equivalence to the reference biological medicine is deemed sufficient, the PBAC may recommend a biosimilar medicine be given an 'a' flag allowing substitution at the point of dispensing.[8]

Savings made from biosimilar medicines use in Australia could be **reinvested into other areas of health** – e.g. expanded access to existing biological medicines or funding of new treatments.

GBMA EDUCATION

BIOSIMILAR MEDICINES

The Essentials for Healthcare Professionals

Visit the **Biosimilar Hub** for information about biosimilar medicines and how they can contribute to a sustainable healthcare system.

biosimilarhub.com.au

Biosimilar medicine facts

>700M

Patient-days of clinical experience in Europe since 2006.[5]

---

systematic literature review

90 studies

evaluating 14,225 patients treated with biological medicines for 14 indications concluded the risk of immunogenicity-related safety concerns or diminished efficacy was unchanged after switching from a biological medicine to its biosimilar.[9]

ARTG APPROVED 2010

In 2010, The Therapeutic Goods Administration approved the first biosimilar medicine for use.[6]

References: 1. European Medicines Agency. *Guideline on similar biological medicinal products Containing Biotechnology-Derived Proteins as Active Substances: Non-Clinical and Clinical Issues.* Effective 1 July 2015. Available at https://www.ema.europa.eu/en/similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non. Accessed April 2019. **2.** Aust Gov't DoH. TGA. *Biosimilar medicines regulation. v2.2 April 2018.* Available at https://www.tga.gov.au/sites/default/files/biosimilar-medicines-regulation.pdf. Accessed April 2019. **3.** Dörner T, *et al. Ann Rheum Dis* 2013; 72(3):322–8. **4.** Schneider CK, *et al. Ann Rheum Dis* 2013; 72(3): 315–18. **5.** Medicines for Europe information based on EMA Post-authorisation Safety Update Reports (PSURs) reported by Adrian van den Hoven. *Biosimilar medicines clinical use: an experience based-EU perspective.* FDA Presentation 13, July 2017, Washington D.C., USA. Available at http://www.medicinesforeurope.com/docs/20170713%20-%20Biosimilar%20Medicines%20Group,%20EU%20experience-AVH-US%20FDA%20Adcom.pdf. Accessed February 14, 2019. **6.** Aust Govt DoH. *Which biosimilar medicines are available in Australia?* Available at http://www.health.gov.au/internet/main/publishing.nsf/content/biosimilar-which-medicines-are-available-in-australia. Accessed March 2019. **7.** Aust Govt DoH: TGA. *Risk management plans for medicines and biologicals. v3.3 March 2019.* Available at https://www.tga.gov.au/publication/risk-management-plans-medicines-and-biologicals. Accessed April 2019. **8.** NPS Medicinewise - RADAR: Brand equivalence - 'a' flagging explained. 1 August 2013. Available at https://www.nps.org.au/radar/articles/brand-equivalence-a-flagging-explained. Accessed April 2019. **9.** Cohen HP, *et al. Drugs* 2018; 78(4): 463–78.

GBMA EDUCATION

GBMA Education Ltd
PO Box 87, Deakin West ACT 2600
biosimilarhub.com.au

May 2019
ART7718c